Diabetes Treatment Articles & Analysis
32 news found
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. ...
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into ...
This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide represents a paradigm shift in the treatment of type 2 diabetes, as it targets the root causes of the disease rather than ...
Huateng Pharma proudly announces the launch of a groundbreaking suite of anti-diabetes intermediates, featuring key compounds such as Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide. Emphasizing the potential impact on diabetes drug development, Huateng Pharma's Research and Development Director expressed enthusiasm, stating, "Our new line of ...
We have seen promising positive results of aflibercept 8 mg given at extended treatment intervals in patients with neovascular age-related macular degeneration and diabetic macular edema, so it is important that we also evaluate its potential in retinal vein occlusion,” said Dr. ...
ByBayer AG
Blood tests are the cornerstone of routine and preventive care services, as about 70% of medical decisions depend on lab tests for diagnosis or treatment. The challenge is how to get that data into the hands of a telehealth provider without having to schedule additional lab visits and follow-up appointments to discuss the test results. ...
Classification of fractional lasers From the perspective of treatment methods, fractional laser is divided into two types: peeling and no peeling. ...
The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot & Ankle Orthopaedics. 2018;3:3. doi:10.1177/2473011418788864 2.Sundararajan PP, Porter BM, Grant KA, et al. ...
(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting featuring UBX1325 as a potential treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), ...
(Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood glucose levels and avoid serious complications, such as loss of ...
Phase 3 Oral Insulin (ORMD-0801) Trials for the Treatment of Type 2 Diabetes: Over 75% Enrollment Completed ORA-D-013-1, the larger of two concurrent Phase 3 oral insulin trials, has enrolled over 75% of the 675 subjects planned for the ...
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of improvements in blood glucose, weight, and broader metabolic parameters with no device- or procedure-related adverse events in long-term follow-up after ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer ...
The combination of ACP-01, an autologous angiogenic cell precursor that has demonstrated improvement of angiogenesis in the heart and limbs of individuals who suffer from ischemia, and cell transplants from human islets or stem cells, hold huge promise in the treatment of diabetes. Following technology transfer, the team will create a new product by combining ...
Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. ...
(NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). ...
(NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that UnitedHealthcare, the largest private health insurance company in the United States, will provide coverage for the company's high-frequency 10 kHz Therapy for the treatment of PDN (Painful ...
(NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System. ...
(TASE: KDST), a clinical stage cell therapy company developing cell therapy treatments for ALS and diabetes, announced today that the Company held a preliminary meeting with the FDA (INTERACT) on October 7, 2021 regarding IsletRx, the company’s cell therapy product in development for the treatment of diabetes. ...
AOTI participated both as a sponsor and exhibitor at these events that were conducted in a hybrid format, where attendance could be either in person, or virtually, to allow for the greatest clinician engagement, something that has now become standard during the ongoing COVID-19 pandemic. The prestigious Malvern Diabetic Foot Conference, the world’s longest standing ...